Still A COVID-19 Game Changer? UK’s Cautious Launch Of MSD’s Antiviral Lagevrio
Efficacy In Vaccinated Population Unproven
The oral therapy is likely to be a useful addition to the COVID-19 armamentarium, but hopes of it being a ‘game changer’ now look overly optimistic.
You may also be interested in...
Merck and Lilly tackle some early challenges before striking voluntary licensing deals for COVID-19 therapies with Indian firms. Data around the use of these drugs in low- and middle-income countries could also potentially make them ‘more acceptable’ elsewhere, experts say.
While Merck & Co’s Lagevrio’s results declined after an interim readout, Pfizer’s oral COVID-19 candidate Paxlovid has maintained its strong performance in protecting high-risk patients from hospitalization or death.
Adagio Therapeutics and Gritstone bio are two companies who could add to the armamentarium against Omicron.